GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (OSTO:CANTA) » Definitions » Policy Acquisition Expense

Cantargia AB (OSTO:CANTA) Policy Acquisition Expense


View and export this data going back to 2015. Start your Free Trial

What is Cantargia AB Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


Cantargia AB Business Description

Traded in Other Exchanges
Address
Scheelevagen 27, Lund, SWE, 223 63
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, as well as its antibody platform CANxx.